Sonomax Technologies Inc

Sonomax Technologies Inc. engages in the development and licensing of intra-ear technology for hearing protection, hearing enhancement, and other auditory applications. The company offers custom-fitted hearing protection and communication enhancement products; and functional accessories, such as Sonomax Self-Fit hearing protection faceplate to support third party acoustic tube radio solutions and Sonomax Quick-Fit lubricant. It also provides SonoPass proof of performance software for validating earpiece performance; and earpiece solutions that are plug and play with multiple radio systems. Sonomax Technologies Inc. sells its products through industrial wholesalers, CE retail distributors, and OEMs primarily in Australia, Canada, Europe, and the United States. The company was formerly known as Sonomax Hearing Healthcare Inc. and changed its name to Sonomax Technologies Inc. in March 2010. The company was founded in 1998 and is headquartered in Montreal, Canada.

Sonomax Technologies Inc trades as SXHHF on OTC. The company is classified in Healthcare / Medical - Specialties and reports in USD.

The current profile places the business in Medical - Specialties. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $842,538 of revenue and -$6.04M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Sonomax Technologies Inc can be compared against peers such as Amarantus BioScience Holdings, Inc., Baseline Productions, Inc., Decision Diagnostics Corp., iBX Group, Inc., Interactive Health Network, Medical Imaging Corp..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $38,133, beta of 233.54, and return on equity of +88.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

SXHHF currently shows total debt of $5.31M and beta of 233.54. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.sonomax.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.